Category | Secukinumab 150 mg subcutaneous (n=72) | Secukinumab 75 mg subcutaneous (n=73) | Placebo (n=74) |
Age in years, mean±SD | 41.9±12.5 | 44.4±13.1 | 43.6±13.2 |
Male, n (%) | 46 (63.9) | 51 (69.9) | 56 (75.7) |
Caucasian, n (%) | 69 (95.8) | 70 (95.9) | 70 (94.6) |
Weight in kg, mean±SD | 82.3±18.0 | 81.5±17.4 | 80.3±15.2 |
Time since diagnosis (years), mean±SD | 7.0±8.2 | 5.3±7.4 | 6.4±8.9 |
HLA-B27 positive, n (%) | 57 (79.2) | 53 (72.6) | 58 (78.4) |
Anti-TNF-naïve, n (%) | 44 (61.1) | 45 (61.6) | 45 (60.8) |
Disease activity | |||
Total BASDAI score, mean±SD | 6.6±1.5 | 6.6±1.3 | 6.8±1.3 |
hsCRP (mg/L), median (min–max) | 7.5 (0.4–237.0) | 5.7 (0.5−86.2) | 8.3 (0.5−84.6) |
Total back pain score (0–100 mm scale), mean±SD | 66.2±16.7 | 65.1±17.7 | 69.2±18.8 |
N, number of randomised subjects.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; HLA, human leucocyte antigen; hsCRP, high-sensitivity C reactive protein; TNF, tumour necrosis factor.